Item 7.01. Regulation FD Disclosure.

On January 19, 2023, Panbela Therapeutics, Inc. (the "Company") issued a press release announcing that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has issued the Adoption of Commission Implementing Decision relating to the designation of ivospemin (SBP-101) as an orphan medicinal product in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (PDA). The U.S. Food and Drug Administration previously granted orphan drug designation to SBP-101. The text of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

The information contained in this item 7.01 and Exhibit 99.1 is being furnished, and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under Section 18. Furthermore, the information contained in this Item 7.01 and Exhibit 99.1 shall not be deemed to be incorporated by reference into the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.





  (d) Exhibits.



Exhibit No.                        Description                        Method of Filing
   99.1         Press Release dated January 19, 2023                     Furnished
                                                                       Electronically
    104       Cover Page Interactive Data File (embedded within the
              Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses